探索医疗保险计划对生物相似采用率的影响
Jeremy Costin1, Morgane C Mouslim2, Mariana P Socal3
1Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
医疗保险计划的设计显著影响生物类似药的采用. 低灵活性计划,如健康维护组织 (HMO) 和专属提供者组织 (EPO),鼓励患者转换或启动生物类似药.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 生物药物和生物类似药物
背景情况:
- 研究了医疗保险计划类型对美国生物类似药的采用影响.
- 研究了计划灵活性,成本,表单设计和网络如何影响生物类似覆盖范围.
研究的目的:
- 对于六种生物生物仿制药对的转换或启动生物仿制药的患者进行表征.
- 评估不同医疗保险计划设计对生物类似药物吸收的影响.
主要方法:
- 利用了从2015年到2019年的美国索赔数据.
- 采用顺序回归模型来分析健康计划与生物类似药的采用之间的关系.
主要成果:
- 发现不那么灵活的保险计划,包括健康维护组织 (HMO) 和专属提供者组织 (EPO),与更高的患者转换率和生物类似药的启动率有关.
- 发现了计划刚性和生物类似药物吸收增加之间的相关性.
结论:
- 强调医疗保险计划设计在推动生物类似药的采用方面发挥的关键作用.
- 强调需要制定战略计划,以促进生物类似药的利用.
更多相关视频
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
相关概念视频
Bioequivalence: Overview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioavailability: Overview
Factors Influencing Bioavailability: First-Pass Elimination
Biopharmaceutics and Pharmacokinetics: Overview
